18 results about "Multiple administration" patented technology

The disclosure provides compositions and improved methods for the treatment of cancer comprising administering to a patient the fusion protein of SEQ ID NO: 1 at a less frequent dosing schedule (i.e., a single administration every three weeks or multiple administrations on non-consecutive days).

Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.

The invention discloses a novel hydrochlorothiazide dosage form and a method for preparing the novel hydrochlorothiazide dosage form, the novel hydrochlorothiazide dosage form with good compressibility is prepared from hydrochlorothiazide, an adhesive, a filling agent and other raw materials through top spray fluidized bed granulation and other preparation methods, and the novel hydrochlorothiazide dosage form has the advantages that the novel hydrochlorothiazide dosage form has obvious curative effect on patients suffering from edema, hypertension and diabetes insipidus; according to the present invention, the pharmaceutical composition can be subjected to multiple administration at a small dose, can be subjected to counting administration especially for people with large individual metabolism difference, such as old people and children, can achieve accurate administration, can improve the medication compliance for people with difficulty in taking conventional preparations, and has characteristics of simple method, easily available raw materials, and easy industrial production.

The invention relates to the technical field of gynecological disease adjuvant therapy instruments, in particular to a vagina drug delivery device which comprises a tube body, a drug storage bag, a threaded push rod, an injection tube, a rotating assembly, a protective cap and a liquid storage bag, a fixing ring is installed at one end of the tube body, and internal threads are arranged on the inner wall of the fixing ring; according to the vagina drug delivery device, through the scale strip on the outer wall of the first threaded sleeve, a user can intuitively set the needed drug delivery dosage, rotate the rotating cylinder anticlockwise to enable the first threaded sleeve to stretch out, observe the scale strip to be adjusted to the preset position, and the user can conveniently and rapidly deliver the drug delivery dosage. The liquid storage bag is filled with the medical lubricant, the medical lubricant is adhered to the outer wall of the injection tube through the sponge ring, friction and discomfort during insertion are reduced, and the acceptability and compliance of a patient are improved, especially under the condition that multiple times of administration are needed, through the design, the dosage of the liquid storage bag is ensured to be accurate, and the liquid storage bag is filled with the medical lubricant and is adhered to the outer wall of the injection tube through the sponge ring.

The present disclosure describes methods of treatment (e.g., combination treatment) by ferroptotic induction, as well as compositions and dosing regimens that are part of such methods. Surprisingly, it is presently found that delaying administration of a ferroptosis-inducing agent until after starting hormone therapy results in enhanced ferroptotic induction in a subject. Thus, in certain embodiments, combination therapies are presented herein that include multiple administration steps whereby a ferroptosis-inducing agent is administered some time after hormone therapy has begun.

The invention discloses a hydrochlorothiazide micro-tablet preparation and a method for preparing hydrochlorothiazide micro-tablets, the hydrochlorothiazide micro-tablets with good compressibility are prepared from hydrochlorothiazide, an adhesive, a filling agent and other raw materials through top-spraying fluidized bed granulation and other preparation methods, and the hydrochlorothiazide micro-tablets have the advantages that the hydrochlorothiazide micro-tablets have no toxic or side effects on patients suffering from edema, hypertension and diabetes insipidus; according to the present invention, the pharmaceutical composition can be subjected to multiple administration at a small dose, can be subjected to counting administration especially for people with large individual metabolism difference, such as old people and children, can achieve accurate administration, can improve the medication compliance for people with difficulty in taking conventional preparations, and has characteristics of simple method, easily available raw materials, and easy industrial production.

Disclosed is an apparatus for determining a dosage regimen of an engineered virus-based nanoparticle composition for the treatment of rheumatoid arthritis. The apparatus may include at least one processor. The apparatus may include a memory communicatively connected to the processor, the memory including instructions for configuring the at least one processor to obtain a plurality of data regarding a plurality of dosage regimens of an engineered virus-based nanoparticle composition for the treatment of rheumatoid arthritis, compare the plurality of dosage data, and determine a critical dosage.

The utility model relates to the technical field of glycerine enema, in particular to glycerine enema capable of being dosed repeatedly, which comprises a liquid storage ball, an anti-leakage mechanism arranged above the liquid storage ball and a complete extrusion mechanism arranged above the liquid storage ball, the anti-leakage mechanism comprises a connecting pipe, the connecting pipe is fixedly connected to the upper end of the liquid storage ball, and the connecting pipe is connected with the complete extrusion mechanism. The connecting pipe is rotationally arranged in the rotating sleeve, a first through groove is formed in the connecting pipe, a connecting ring is fixedly connected to the upper end of the rotating sleeve, a fixing plate is fixedly connected to the inner wall of the connecting ring, a second through groove is formed in the fixing plate, and the area of the second through groove is the same as that of the first through groove; the upper end of the connecting ring is fixedly connected with an extrusion pipe, and a lengthening pipe is installed at the upper end of the extrusion pipe. According to the enema capable of dosing for multiple times, the enema can be conveniently dosed, the dosed enema can be sealed subsequently, pollution and waste caused by automatic extrusion of leaked enema are avoided, and the practicability and the closeness of the enema are improved.

The present invention discloses a crystalline form of a compound, as well as its preparation and use. The compound has the structure shown in Formula I. The crystalline form has relatively good solid-state stability and flowability, relatively low hygroscopicity, and relatively good solubility, making it advantageous for the preparation and storage of pharmaceutical formulations. Furthermore, the crystalline form has excellent pharmacokinetic properties, relatively excellent safety during repeated administration, and can be administered via multiple administration routes (e.g., injection, oral administration). It is available in a wide range of formulations, and has particularly high oral bioavailability, making it highly valuable for practical applications. The crystalline form can be used as a JAK inhibitor to develop drugs for the prevention and / or treatment of inflammatory diseases, tumors, autoimmune diseases, and allergic diseases in humans and / or animals. [Formula 1] JPEG2025542332000054.jpg45170

The present invention discloses a coupled prodrug, nanoparticles, pharmaceutical composition, preparation method and application based on the structure of taxane-artemisinin derivatives, wherein the coupled prodrug structure is as follows: P-L 1 ‑(CH 2 ) n ‑X‑(CH 2 ) m ‑L 2 ‑A easily achieves the spatiotemporal coordinated transport of different drugs through different connecting arms, and has controllable drug release behavior, which improves the tumor treatment effect. At the same time, it improves the drug solubility by self-assembly into nanoparticles, and solves the biocompatibility, preparation method complexity and safety problems caused by solvents and carrier materials. It can be prepared into drugs for multiple administration routes such as oral, inhalation, injection, ophthalmic, transdermal, mucosal, etc., and is used in the prevention and treatment of various tumors.

Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and / or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and / or administering the cells expressing the second receptor to a subject having received the first administration. The methods can provide various advantages, such as improved efficacy in the context an immune response in the subject against the first or prior receptor and / or in the context of antigen loss, downregulation, or modification, following a first or prior administration.

The invention discloses a series of novel compounds which contain beraprost and a nitric oxide donor and are shown in the following formula I. The invention relates to the series of compounds as well as pharmaceutical compositions and application thereof. The beraprost sodium and NO donor combined drug provided by the invention overcomes the defects that the beraprost sodium is short in clearing half-life period, the number of times of administration per day is large, the curative effect has a saturated capping effect, and NO is a gas which is rapidly decomposed and metabolized in a solution and is short in half-life period, and the new compound reduces the dosage and the administration frequency of original beraprost administration, improves the curative effect of the beraprost sodium and the NO donor, and improves the curative effect of the beraprost sodium and the NO donor. Meanwhile, by utilizing the smooth muscle relaxation effect caused by NO molecules released by the compound in vivo, the synergistic effect of the two drugs is exerted through the dual effects, and the effectiveness and safety of the drug are improved.

This application relates to the field of biomedical technology, proposing a compound that targets and degrades RALBP1 protein, its preparation, and its application. The compound is the compound shown in formula (I), or its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs. The compound of this application belongs to the PROTAC drug category, which can target small molecule conjugates of RALBP1, thereby inducing RALBP1 degradation and achieving effective prevention or treatment of acute myeloid leukemia. Simultaneously, the compound of this application can be used in oral formulations; through structural optimization, it balances drug activity and oral convenience. Single or multiple administrations can produce significant tumor-suppressive effects, demonstrating broad application prospects. (I)

To prevent a patient from forgetting to take a medicine, and warn the patient to recognize a particularly important administration timing among multiple administration timings.SOLUTION: An information processing device includes at least one processor. The at least one processor associates, based on input administration information for a plurality of medicines, an administration timing that meets a predefined condition among a plurality of administration timings which are timings of taking at least one of the plurality of medicines, with warning information which is information for warning the patient to recognize the medicine to be taken among the plurality of medicines at the administration timing. The at least one processor then outputs the associated warning information and the administration timing to an output device.SELECTED DRAWING: Figure 6

Described are viral vectors, compositions, kits, and methods or using the vectors, compositions, kits to modulate immune response in a subject. The viral vectors include therapeutic recombinant adeno-associated viruses (rAAVs) and tolerance inducing gene therapy vectors. The therapeutic rAAVs and tolerance inducing gene therapy vectors can be used to deliver one or more therapeutic nucleic acids to the subject. The tolerance inducing gene therapy vectors induce immune-specific tolerance to the therapeutic rAAVs to improve efficacy of the therapeutic rAAVs and allow for multiple administrations of the therapeutic rAAVs with little or no associated immune response to the therapeutic rAAVs. The therapeutic rAAVs can be used to administer a therapeutic effect to the subject.

This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered multiple times to an organism requiring tumor treatment, at a radioactive dose that avoids dose-limiting toxicity, as determined on the basis of hematological parameters. The multiple administration preferably consists of intermittent administration at time intervals allowing the hematological parameters to return to a normal range.

The present invention provides a long-acting liposome composition for treating pain or stimulation in a joint of a subject suffering from a joint disorder, in particular osteoarthritis. The compositions comprise phosphatidylcholine lipids as the only active ingredient and provide pain relief upon single administration or multiple administration at a frequency of once every four to twelve months.

The present invention provides an antibacterial drug composition, colloidal particles surrounded by an interfacial film, and a preparation method and application thereof, and belongs to the technical field of antibacterial drugs. The antibacterial active drug composition or colloidal particles uses a polypeptide antibiotic composed of 3-40 amino acid molecules as an antibacterial active ingredient, a polymer-conjugated lipid as a cosolvent, and a sugar ester compound and / or a sugar acid compound or its salt as a stabilizer. Under the joint action of the stabilizer and the cosolvent, the antibacterial activity and in vivo safety of the drug are significantly improved, and the antibacterial activity of the drug against drug-resistant Gram-negative bacteria is improved; it is obtained by dissolving and mixing, and the process is simple, reproducible, and commercial production is easy to achieve. The present invention significantly reduces the toxic and side effects of the drug on the basis of not changing the in vivo PK characteristics of polymyxin drugs, and the therapeutic dose can reach 3-5 times of the conventional dose, can be used for cells, poultry, beasts and humans, and is administered by a variety of administration routes to meet clinical drug needs.